April 10, 2017 / 2:17 PM / 8 months ago

BUZZ-IntelliPharmaCeutics: Drops as patent suit delays FDA decision on drug

** Canadian drug developer’s U.S.-listed shares down ~17 pct at $1.89

** IntelliPharmaCeutics says FDA decision on marketing approval for its opioid painkiller Rexista stayed for 30 months after Purdue Pharmaceuticals filed patent suit

** Stock set for worst day since Aug 2015, with volumes nearing 3x their 25-DMA

** Rexista is a long-acting formulation of oxycodone and is designed to be abuse-deterrant; Purdue sells the blockbuster OxyContin, which is also an long-acting version of oxycodone

** Up to Friday’s close, IPCI’s Nasdaq-listed stock had fallen about 20 pct this year

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below